Expert Review of Anti-Infective Therapy

metrics 2024

Transforming Knowledge into Action Against Pathogens

Introduction

Expert Review of Anti-Infective Therapy, published by Taylor & Francis Ltd, is a leading journal in the field of infectious diseases, microbiology, and virology, boasting an impressive impact factor and ranking in the Q1 category across multiple disciplines. With an ISSN of 1478-7210 and E-ISSN 1744-8336, this journal has become a vital resource for researchers, professionals, and students aiming to advance their understanding of anti-infective therapies. Since its inception in 2003, the journal has provided critical insights, evidence-based reviews, and forward-thinking perspectives that contribute significantly to the ongoing efforts in combating infectious diseases. As of 2023, it ranks #36 out of 344 in Medicine/Infectious Diseases and maintains high percentiles in various other categories, reflecting its influence and reach within the scientific community. Although not an Open Access journal, its rich content is delivered through various academic libraries, sustaining its commitment to disseminating knowledge in the face of global health challenges. For those committed to innovation in the field, the Expert Review of Anti-Infective Therapy offers a platform that blends thorough research with practical applications, making significant strides in the fight against infectious pathogens.

Metrics 2024

SCIMAGO Journal Rank1.26
Journal Impact Factor4.20
Journal Impact Factor (5 years)5.70
H-Index96
Journal IF Without Self4.20
Eigen Factor0.01
Normal Eigen Factor1.21
Influence1.34
Immediacy Index1.30
Cited Half Life6.30
Citing Half Life5.20
JCI0.74
Total Documents2434
WOS Total Citations6152
SCIMAGO Total Citations22339
SCIMAGO SELF Citations442
Scopus Journal Rank1.26
Cites / Document (2 Years)5.29
Cites / Document (3 Years)5.50
Cites / Document (4 Years)5.51

Metrics History

Rank 2024

Scopus

Infectious Diseases in Medicine
Rank #36/344
Percentile 89.53
Quartile Q1
Microbiology in Immunology and Microbiology
Rank #23/182
Percentile 87.36
Quartile Q1
Microbiology (medical) in Medicine
Rank #19/140
Percentile 86.43
Quartile Q1
Virology in Immunology and Microbiology
Rank #14/80
Percentile 82.50
Quartile Q1

IF (Web Of Science)

INFECTIOUS DISEASES
Rank 28/132
Percentile 79.20
Quartile Q1
MICROBIOLOGY
Rank 47/161
Percentile 71.10
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 75/354
Percentile 79.00
Quartile Q1

JCI (Web Of Science)

INFECTIOUS DISEASES
Rank 51/132
Percentile 61.36
Quartile Q2
MICROBIOLOGY
Rank 68/161
Percentile 57.76
Quartile Q2
PHARMACOLOGY & PHARMACY
Rank 149/354
Percentile 57.91
Quartile Q2

Quartile History

Similar Journals

Infection and Drug Resistance

Advancing the fight against infections and drug resistance.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1178-6973Frequency: 1 issue/year

Infection and Drug Resistance, published by DOVE MEDICAL PRESS LTD, is a leading open-access journal dedicated to the critical fields of infectious diseases and pharmacology. Since its establishment in 2008, this journal has emerged as a vital resource for researchers, professionals, and students alike, offering thorough insights into the mechanisms of drug resistance and the effectiveness of various therapeutic interventions. With an impressive 2023 impact factor placing it in the Q2 category across multiple relevant disciplines, including Infectious Diseases and Pharmacology, it serves as a significant platform for high-quality research dissemination. Infection and Drug Resistance aims to foster a deeper understanding of the evolving challenges in managing infectious diseases and enhancing drug efficacy, contributing to the global discourse on public health. The journal's commitment to open access ensures that vital knowledge is readily available to promote broader scholarly engagement and innovation.

Infectious Diseases and Clinical Microbiology

Transforming discoveries into clinical applications for better health.
Publisher: DOC DESIGN INFORMATICS CO LTDISSN: 2667-646XFrequency: 4 issues/year

Infectious Diseases and Clinical Microbiology is a pivotal journal dedicated to advancing our understanding of infectious diseases through rigorous scientific research and clinical practices. Published by DOC DESIGN INFORMATICS CO LTD, this journal serves as a vital platform for researchers, healthcare professionals, and students keen on enhancing their knowledge of microbiological sciences and the clinical implications of infectious agents. With an ISSN of 2667-646X, it aims to disseminate significant findings in the field, enriching the scholarly dialogue surrounding infectious diseases. While currently operating under a traditional access model, the journal encourages global collaboration and knowledge sharing, striving to make a meaningful impact in tackling the challenges posed by infectious diseases. Its content aims to bridge the gap between laboratory research and clinical application, making it an essential resource in the contemporary landscape of global health.

JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION

Fostering collaboration in the fight against infections.
Publisher: ELSEVIER TAIWANISSN: 1684-1182Frequency: 6 issues/year

Welcome to the Journal of Microbiology Immunology and Infection, a premier academic publication established in 1998 and now proudly owned by Elsevier Taiwan. As an Open Access journal since 2016, it provides unrestricted access to groundbreaking research in the fields of immunology, microbiology, and infectious diseases, making it an essential resource for researchers, practitioners, and students alike. The journal holds impressive rankings, including Q1 status in categories such as Infectious Diseases and Microbiology (medical), and a notable 92nd percentile in its Scopus ranking for Medicine - Infectious Diseases. With a dedicated focus on advancing knowledge and fostering collaboration within the scientific community, the Journal of Microbiology Immunology and Infection is committed to publishing high-impact research that significantly influences practice and policy in healthcare and life sciences. The journal is also recognized for its contribution to the ongoing dialogue surrounding contemporary issues in immunology and infection, positioning it as a vital platform for scholarly exchange and innovation.

MIKROBIYOLOJI BULTENI

Fostering Knowledge in Immunology and Microbiology
Publisher: ANKARA MICROBIOLOGY SOCISSN: 0374-9096Frequency: 4 issues/year

MIKROBIYOLOJI BULTENI, with ISSN 0374-9096, is a prestigious academic journal published by the ANKARA MICROBIOLOGY SOC, located in Ankara, Turkey. Established in 1973, this journal has been a vital conduit for disseminating research in the fields of Immunology, Microbiology, and Infectious Diseases, garnering a reputation as a significant contributor to the scientific community. The journal is currently ranked in the Q3 category within Immunology and Microbiology (miscellaneous), and Infectious Diseases, indicating its impactful presence amidst contemporary research. With access options that may be restricted, MIKROBIYOLOJI BULTENI actively welcomes submissions that advance the understanding of critical microbiological principles and practices, thereby supporting both national and international research efforts. Researchers, professionals, and students are encouraged to explore the latest findings shared in this journal, as it continually shapes the landscape of microbiology and infectious disease studies through its comprehensive and rigorous peer-reviewed publications.

Lancet Microbe

Fostering Collaboration for a Healthier Tomorrow
Publisher: ELSEVIERISSN: Frequency: 12 issues/year

The Lancet Microbe is a leading peer-reviewed journal published by ELSEVIER, focused on advancing research in the fields of infectious diseases, microbiology, and virology. Since its inception in 2020, this open-access journal has rapidly achieved a prestigious reputation, evidenced by its impressive rankings in the Scopus Ranks, where it holds positions within the top 10 in multiple categories and boasts high percentiles, reflecting the impact and relevance of its published works. With a quarterly publication schedule, the Lancet Microbe aims to disseminate critical findings and foster innovation within the scientific community, providing a platform for researchers and professionals to share their significant contributions. The journal is committed to facilitating knowledge exchange and accessibility, making it an essential resource for academicians and practitioners dedicated to addressing global health challenges.

JOURNAL OF CLINICAL MICROBIOLOGY

Unveiling Innovations in Clinical Microbiology
Publisher: AMER SOC MICROBIOLOGYISSN: 0095-1137Frequency: 12 issues/year

JOURNAL OF CLINICAL MICROBIOLOGY, published by the American Society for Microbiology, stands as a premier resource for researchers and professionals in the field of medical microbiology. With an illustrious history dating back to 1975, this journal has consistently provided high-impact research, reflecting its status in the Q1 category among microbiology (medical) journals, and an impressive Scopus rank of 14 out of 140, placing it in the 90th percentile. The journal's commitment to unveiling foundational and innovative studies greatly contributes to understanding human health challenges posed by microbial pathogens. Researchers can expect rigorous peer-reviewed articles that cover a spectrum of topics, from diagnostic methods to clinical epidemiology, fostering a deeper understanding of microbiology's role in healthcare. While this journal does not offer open access options, its substantial impact factor underscores its relevance in shaping the conversation in clinical microbiology. The JOURNAL OF CLINICAL MICROBIOLOGY is indispensable for anyone dedicated to advancing their knowledge and practical skills in microbiology.

Microbial Drug Resistance

Transforming Knowledge into Action Against Drug Resistance
Publisher: MARY ANN LIEBERT, INCISSN: 1076-6294Frequency: 10 issues/year

Microbial Drug Resistance, published by MARY ANN LIEBERT, INC, is a pivotal journal that explores the critical intersection of microbiology and pharmacology with a keen focus on antibiotic resistance and related issues. Since its inception in 1995, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for innovative studies that inform the global response to antimicrobial resistance. With a commendable position in the Category Quartiles, ranked Q2 in Medicine (miscellaneous) and Q2 in Pharmacology for 2023, it caters to a multidisciplinary audience by addressing the implications of microbial resistance within various medical contexts. Although currently non-Open Access, the journal allows subscribers and institutions to access high-quality, peer-reviewed research, directly impacting policy and practice in healthcare settings. Committed to advancing our understanding and combating the challenges posed by resistant microbes, Microbial Drug Resistance remains an essential publication in the fields of microbiology, immunology, and pharmacology.

Infectious Diseases

Elevating Knowledge in the Dynamic Field of Infectious Diseases
Publisher: TAYLOR & FRANCIS LTDISSN: 2374-4235Frequency: 12 issues/year

Infectious Diseases, published by TAYLOR & FRANCIS LTD, is a leading academic journal dedicated to advancing research in the field of infectious diseases and microbiology. With an impressive impact factor and categorized in Q1 in multiple areas including Immunology and Microbiology, this journal serves as a critical platform for researchers, practitioners, and students to disseminate their findings and stay abreast of current advancements. The journal is recognized for its rigorous peer-review process and aims to foster innovation and collaboration across disciplines from 2015 to 2024. It boasts a robust Scopus ranking, positioning it favorably among the top-tier of journals in the relevant fields, making it an essential resource for anyone involved in infectious disease research. Access options are available, ensuring that the latest research is accessible to a global audience, thus emphasizing the journal's commitment to promoting knowledge and understanding in the ever-evolving landscape of infectious diseases.

GERMS

Enhancing public health through collaborative research initiatives.
Publisher: EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASESISSN: 2248-2997Frequency: 4 issues/year

GERMS is a multidisciplinary journal published by the EUROPEAN ACAD HIV-AIDS & INFECTIOUS DISEASES, dedicated to advancing knowledge in the fields of epidemiology, immunology, infectious diseases, and microbiology. Since its inception in 2011, the journal has provided a crucial platform for researchers and practitioners to share innovative studies, clinical findings, and public health insights, with an eye on improving health outcomes globally. With an ISSN of 2248-2997 and a consistent publication trajectory leading up to 2024, GERMS is recognized in the third quartile across several categories, reflecting its growing impact and relevance in the scientific community. Authors and readers benefit from a range of access options, fostering the dissemination of vital research findings. As a journal situated in Romania, it also addresses regional health challenges while contributing to the broader discourse on infectious diseases and public health. GERMS is not just a repository of knowledge, but a vital resource for those engaged in combating infectious diseases and promoting health equity.

Infection and Chemotherapy

Empowering Knowledge for Better Health Outcomes
Publisher: KOREAN SOC ANTIMICROBIAL THERAPYISSN: 2093-2340Frequency: 4 issues/year

Infection and Chemotherapy, an esteemed journal published by the Korean Society of Antimicrobial Therapy, focuses on the dynamic fields of infectious diseases and pharmacology. With an ISSN of 2093-2340 and an E-ISSN of 2092-6448, this peer-reviewed, open-access journal has been providing a crucial platform for research dissemination since 2008. Based in South Korea, it boasts a significant impact in the academic community, as evidenced by its Q2 ranking in both Infectious Diseases and Pharmacology categories for 2023. It holds a Scopus rank of 64 out of 272 in Pharmacology and 98 out of 344 in Infectious Diseases, showcasing its prominence and the quality of research it publishes. With a focus on advancing scientific knowledge, Infection and Chemotherapy is committed to fostering essential dialogues among researchers, clinicians, and students, making it a vital resource for those engaged in the fight against infectious diseases and the development of effective therapeutic protocols.